3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
9
Head & Neck
6
Thoracic
4
Breast
4
Endocrine
3
CNS
2
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
NET
1
Lymphoid
1
Genitourinary
1
Dermatologic
1
Conditions
Neuroendocrine Tumors
102
Carcinoid Tumor
22
Neoplasms
16
Neoplasm Metastasis
10
Gastro-enteropancreatic neuroendocrine tumor
10
Carcinoma, Neuroendocrine
9
Adenoma, Islet Cell
9
Pancreatic Neoplasms
7
Carcinoma
7
Pheochromocytoma
6
Paraganglioma
6
Neuroblastoma
6
Colorectal Neoplasms
6
Carcinoma, Islet Cell
6
Somatostatinoma
5
Gastrointestinal Neoplasms
5
Vipoma
4
Small Cell Lung Carcinoma
4
Serotonin Syndrome
4
Neuroectodermal Tumors, Primitive
4
Melanoma
4
Medulloblastoma
4
Lung Neoplasms
4
Intestinal Neoplasms
4
Gastrinoma
4
Carcinoma, Non-Small-Cell Lung
4
Adenocarcinoma
4
Prostatic Neoplasms
3
Neuroectodermal Tumors
3
Neoplasms, Nerve Tissue
3
Interventions
pralsetinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Endocrine Gland Neoplasms
×
NET
×
Clear all
NCT03037385
2025-05-31
ARROW
Hoffmann-La Roche
Phase 1/2
Completed
590 enrolled
58 charts
3 FDA